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Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder that presents with hemolytic anemia, marrow
failure and thrombophilia. During acute attacks, corticosteroid can alleviate the hemolytic paroxysm, but the
prolonged administration induces serious toxicity including immunosuppression. So American thoracic society (ATS)
for tuberculosis (TB) recommends prophylactic anti-TB medication in patients with a long-term steroid therapy.
However, in the patient who was treated for active TB in the past, there are no guidelines of the test for
determining patients who have latent TB infection (LTBI) and no recommendations of TB prophylaxis if there is no
evidence of reactivation at present. A 40-year-old male patient presented with fever and aggravated weakness for a
week. He was diagnosed with PNH a month ago and took corticosteroid for 3 weeks. In the past, he was diagnosed
with pulmonary TB and completely cured after treatment. According to guideline, he was not indicated with TB
prophylaxis. However, he caught miliary TB, progressed to acute respiratory distress syndrome. We experience this
embarrassing case, and emphasize the need to investigate multicentral TB prevalence and to make the guidelines
of anti-TB medication in subgroups of hematologic diseases including PNH.
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Paroxysmal nocturnal hemoglobinuria (PNH) is a rare
acquired clonal hematopoietic stem cell disorder that
presents with hemolytic anemia, venous thrombosis, de-
ficient hematopoiesis and chronic renal disease [1]. It is
a serious chronic disease with high morbidity and mor-
tality. Hematopoietic stem cell transplantation is only a
curative treatment. The treatment is personalized and
directed towards the specific complications. Sometimes,
PNH patients have acute attacks. Corticosteroid and an-
drogen can be lessen a hemolytic paroxysm and improve
hemoglobin levels in about 60% of PNH patients. How-
ever, the required doses of corticosteroid are high, and a
long-term continuous administration on a daily basis is
difficult due to its toxicities [2,3]. Owing to immunosup-
pressive effect of corticosteroid, American thoracic society
(ATS) for tuberculosis (TB) recommends anti-TB* Correspondence: gsj1117@eulji.ac.kr
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reproduction in any medium, provided the ormedication in patients used prednisone more than 15 mg/
day over a month [4]. Nevertheless, these guidelines show
only the treatment principles, in clinical practice, there are
some problems to decide the test or management in spe-
cial groups including hematologic diseases. In addition,
the prevalence of miliary TB in malignant disease is 3
times higher than in general population and its mortality
rate is about 25–30% in adults [5].
We experienced a PNH patient with acute attack. He
received corticosteroid for 3 weeks to control hemolysis.
In the past, he was diagnosed with pulmonary TB and
we investigated LTBI (latent TB infection). He was not
indicated with anti-TB medication [6], but after im-
munosuppressive drug for 3 weeks, he suffered from
miliary TB. So we report this difficult and embarrassing
case with literature review of TB associated with
hematologic disease.Case report
A 40-year-old Asian male patient presented with fever
and more aggravated generalized weakness for 1 week. A. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eralized weakness. He was diagnosed with PNH asso-
ciated with another bone marrow disorder (aplastic
anemia). For control of acute hemolysis, red cells trans-
fusion and immunosuppressive drugs (corticosteroid and
danazol) were prescribed and he was discharged after
stabilized. At that time, his chest X-ray showed old pul-
monary calcified nodules in both lung field (Figure 1).
He was diagnosed with pulmonary TB about 21 years
ago and he was completely cured after anti-TB medica-
tion (Isoniazid, Ethambutol, Rifampicin, Pyrazinamide)
for 6 months. On readmission, vital signs were followed;
BP 140/80 mmHg, pulse rate 76 beats/min, respiration
rate 20 times/min, and body temperature 39.1°C.
Jaundice was observed in both sclera, and breath sounds
were decreased in both lung field. The laboratory find-
ings revealed white blood cells, 720/uL (segment neutro-
phil 75.6%; lymphocytes 15.7%); hemoglobin, 9.6 g/dL;
and platelets, 55,000/uL. AST/ALT, total bilirubin and
LDH were 167/312 IU/L, 3.9 mg/dL and 2,543 IU/L re-
spectively. Blood urea nitrogen and serum creatinine
were 20.3 mg/dL and 1.4 mg/dL. In chest radiographs,
the miliary nodules were observed in both lung field
(Figure 2A). Chest CT scan showed miliary nodulation
and patch underlying perinodular ground glass appear-
ance in both lung field, suggestive of miliary TB
(Figure 2B). TB PCR was positive. After 3 weeks ofFigure 1 In chest radiographs, the suspicious old tuberculous
calcified nodule was seen (white arrow).immunosuppressive drugs, he was diagnosed to miliary
TB. Due to elevated liver enzyme, Ethambutol/Moxiflox-
acin/Cycloserine were selected. To expect the rise of
drug effects, supportive care such as G-CSF administra-
tion, blood transfusion and nutritional support were
done. After 5 days of the anti-TB medications, patch
density in chest X-ray was progressed and he complained
of severe dyspnea, nausea, vomiting and aggravated
weakness (Figure 3). We considered ventilator care, but
the patient was tolerable at the 10L of oxygen mask
apply. We added 1st line anti-TB drugs (Isoniazid, Rifam-
picin) stage by stage. After continuous intensive care for
3 weeks, dyspnea was getting better and he needed only
2L of oxygen apply. The chest X-ray has got better. He
was improved and the resistance strain was not seen in 8
weeks after culture. He had taken 1st line anti-TB drugs
(Isoniazid, Ethambutol, Rifampicin) and warfarin in out-
patient of hospital, and nowadays he finished anti-TB
drugs except warfarin (Figure 4).
Discussion
In paroxysmal nocturnal hemoglobinuria (PNH), the ab-
sence of the glycosyl phosphatidylinositol (GPI)-anchored
proteins induces hemolytic anemia, thrombosis and
smooth muscle dystonias. PNH is a chronic condition and
its treatment includes 1) allogeneic bone marrow trans-
plantation, 2) eculizumab, a humanized monoclonal anti-
body against the terminal complement protein C5 [7,8]
and 3) supportive care such as transfusion, iron and folic
acid supplementation and prophylactic anti-coagulation.
However, sometimes patients have acute attacks. Cortico-
steroid can alleviate a hemolytic paroxysm and improve
hemoglobin levels in about 60% of PNH patients. But a
long-term continuous administration of high dose cortico-
steroid is troubled with its toxicity [2]. Due to immunosup-
pression of corticosteroid, CDC recommends prophylactic
anti-TB medication in patients with more than 15 mg/day
prednisone over 1 month [4].
Worldwide, for the elimination of TB, identification
and treatment of latent tuberculosis infection (LTBI) are
essential [9-12]. LTBI is a condition in which a person is
infected with dormant Mycobacterium tuberculosis
organisms, but does not currently have active TB disease
[13]. According to ATS for TB, following patients with
LTBI should be considered for anti-TB medication; HIV
infection, organ transplantation related to immune-
suppressant therapy, recent TB infection within 2 years,
TNF inhibitors. In cellular immunity of TB, lymphocyte
is a major part of immune activity [4,14]. In patients with
hematologic disease, T-cell immunodeficiency was
induced by hematologic disease itself, chemotherapy,
corticosteroid and other underlying diseases [15]. Hahn
et al. reported that the prevalence of active TB in
hematologic disorders was 0.8% in total, with 21.4% in
A B
Figure 2 (A) In chest radiographs, the miliary nodules were observed in both lung field. (B) Chest CT scan showed miliary nodulation and
patch underlying perinodular ground glass appearance in both lung field, suggestive of miliary TB.
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syndrome in Korea. Although in this report, the preva-
lence of TB in the hematologic disorder was not signifi-
cantly different compared with control group, the
incidence of TB in PNH was very high [16]. There are
many controversies in the incidence of TB inFigure 3 Patch density in chest X-ray was progressed,
suggestive of acute respiratory distress syndrome.immunosuppressed patients. In clinical practice, consid-
ering risk and an incidence, the diagnosis and treatment
of LTBI should be determined. However, there is a prob-
lem in determination of prophylactic anti-TB medication,
that is to say limitation of the diagnostic methods for
LTBI in immunosuppressed patients.Figure 4 After anti-tuberculosis medication, chest X-ray showed
improvement.
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tuberculin skin test (TST) as a diagnostic tool for LTBI
in high-risk group and in the U.S. diagnostic guidelines
of 2000, an immunologic test was described. Qunati-
FERON-TB Gold (QFT-G) is an interferon-gamma re-
leasing assay (IGRA) and it was approved by the FDA
for the diagnosis of TB in 2005 and replaced TST
[4,17]. In Korea with high prevalence of TB and high
false positivity of TST due to BCG vaccination, IGRA
replace TST. But IGRA has a limitation in differenti-
ation of active TB from LTBI, and when patient was
treated with LTBI or active TB in the past, it can’t
determine whether or not new infection is developed.
Also in patients with immunosuppression and
complete recovery from TB at the same time, there is
no guideline.
On the other hand, miliary TB accounts for about
1% of all cases of TB and the mortality related to
miliary TB is about 25–30% in adults [5]. Miliary TB
may infect any number of organs, including the lungs,
liver and spleen. Hematologic abnormalities are fre-
quently described and pancytopenia is profound in
hematolgic diseases. In malignant diseases, the inci-
dence of miliary TB is about 3% and it rarely reported
in hematologic diseases [18,19].
In our patient, before the administration of im-
munosuppressive drugs for control of acute hemolysis,
we wanted to perform the test for detection of LTBI
according to CDC for TB. However, since our patient
did not have clinical and radiological evidence of ac-
tive TB and he was completely cured TB in the past,
he was not indicated to test and prophylactic anti-TB
medication. In addition, because anti-TB medication
frequently induces hepatic dysfunction, poor oral in-
take, nausea and vomiting, the administration prophy-
lactic anti-TB medication is very troubled in seriously
ill patient out of guideline. However, he contracted
miliary TB and we were in confusion. The treatment
for TB was not easy because he complained of nau-
sea, vomiting and poor oral intake and his laboratory
findings showed severe pancytopenia and liver dys-
function. Meanwhile, fever is the sign that needs dif-
ferential diagnosis. He had fever at diagnosis of PNH
due to hemolysis and he was checked chest X-ray
regularly (weekly). But, miliary TB was developed in
one week. So in patients with fever and immunosup-
pressive drugs, inspection and chest X-ray at intervals
of 2 or 3 days are needed.
In conclusion, except some advanced country, TB is
endemic disease in worldwide yet. Also, there are dif-
ferences of TB prevalence between the subgroups of
hematologic diseases. So we emphasize the need to
investigate multicentral TB prevalence and to make
an urgent decision of details of the guidelines foranti-TB medication in patients with subgroups of
hematologic diseases including PNH.
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